View Older Stories View More Recent Stories
-
Moderna (MRNA) PT Lowered to $55 at TD Cowen
-
Moderna (MRNA) Tops Q3 EPS by 195c
-
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
-
Bancel To Step Down As Moderna (MRNA) Chief Commercial Officer - Bloomberg
-
Moderna to Present at Upcoming Conferences in November 2024
-
Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA
-
Moderna Named a Top Employer by Science for Tenth Consecutive Year
-
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA)
-
Northwestern University Files Patent Infringement Lawsuit Against Moderna (MRNA) Over mRNA Vaccine Technologies
-
TD Cowen Reiterates Hold Rating on Moderna (MRNA)
-
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
-
GSK (GSK) Sues Moderna (MRNA) for US Patent Infringement Over MRNA Technology in Covid-19 Vaccines - Court Filing
-
Moderna (MRNA) PT Lowered to $55 at Jefferies
-
Moderna (MRNA) Appoints Abbas Hussain to its Board
-
Abbas Hussain Joins Moderna's Board of Directors
-
Moderna (MRNA) and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan
-
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
-
Moderna (MRNA) Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
-
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
-
Moderna (MRNA) Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant
-
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
-
5 takeaways from Moderna's investor day
-
Moderna (MRNA) PT Lowered to $115 at Piper Sandler
-
Oppenheimer Downgrades Moderna (MRNA) to Perform
-
Moderna (MRNA) PT Lowered to $75 at RBC Capital
-
Moderna (MRNA) PT Lowered to $238 at Brookline Capital Markets
-
Moderna (MRNA) PT Lowered to $60 at TD Cowen
-
Jefferies Downgrades Moderna (MRNA) to Hold
-
JPMorgan Downgrades Moderna (MRNA) to Underweight
-
Moderna shares plunge after cutting research budget
-
Evercore ISI Reiterates In Line Rating on Moderna (MRNA)
-
Morgan Stanley on Moderna (MRNA): 'we expect MRNA shares to trade off this morning'
-
Jefferies Reiterates Buy Rating on Moderna (MRNA)
-
Moderna (MRNA) R&D Day Highlights Progress and Strategic Priorities
-
Moderna R&D Day Highlights Progress and Strategic Priorities
-
Moderna (MRNA) option implied volatility elevated into investor meeting
-
Moderna (MRNA) call put ratio 1.9 calls to 1 put into investor meeting
-
Carisma Therapeutics (CARM) and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
-
Moderna (MRNA) option implied volatility elevated into investor meeting
-
Moderna's (MRNA) Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
-
Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
-
Moderna (MRNA) option implied volatility near upper end of range into investor meeting
-
Moderna (MRNA) Reports EMA CHMP's Positive Opinion of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
-
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
-
Moderna (MRNA) call put ratio 2.6 calls to 1 put with focus on September 6 weekly 77 calls
-
Moderna's (MRNA) experimental mpox vaccine reduces severity of disease, early study finds - DJ
-
Moderna (MRNA) Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
-
Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
-
Moderna (MRNA) Announces Taiwanese Approval of its COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
-
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)
